中国疫苗第四款,国药集团武汉所的灭活疫苗第三期实验结束,有效率 72.51%

向问天

日月神教光明左使
VIP
注册
2012-09-04
消息
58,791
荣誉分数
10,681
声望点数
1,273
Sinopharm’s Wuhan institute vaccine shows 72.5% efficacy; CanSino applies for emergency use approval
By Global TimesPublished: Feb 24, 2021 03:32 PM

462cb6ab-f203-4a08-99d4-953616955d15.jpeg

Sinopharm's COVID-19 vaccine. Photo: VCG

Sinopharm's research institute in Wuhan, Central China's Hubei Province on Wednesday said that their inactivated COVID-19 vaccine shows an efficacy of 72.51 percent after two shots in phase III clinical trials.

The institute said on its website that they applied to Chinese drug management authorities for emergency use approval on February 21, which has been officially accepted.

Phase III clinical trials on the vaccine kicked off on July 16, 2020 in several countries, such as the United Arab Emirates.

So far, data from the trials shows that the vaccine can trigger high-titer antibodies in recipients. The neutralizing antibody positive conversion rate reached 99.06 percent after two shots, according to the institute.

Two inactivated COVID-19 vaccines, one was developed by Sinopharm's institute in Beijing and the other by Sinovac, have obtained emergency use approval, reports said.

China's drug management authorities have also officially accepted the application of another producer - CanSino - for conditional marketing of its COVID-19 recombinant adenovirus vector vaccine, the company said on Wednesday. It is China's third vaccine candidate to apply for mass use.

Global Times
 

向问天

日月神教光明左使
VIP
注册
2012-09-04
消息
58,791
荣誉分数
10,681
声望点数
1,273
中国现在总计3款灭活疫苗,1款腺病毒疫苗,后者只需要打一针。
 

billwanhua

资深人士
注册
2005-07-07
消息
2,303
荣誉分数
587
声望点数
273
灭活疫苗有效率低是不是跟毒株单一有关?能不能把巴西英国南非变异的放一起培养灭活?
 

superlover

青春已经谢幕,可我迟迟不愿退场
VIP
注册
2007-08-08
消息
5,469
荣誉分数
660
声望点数
273
我相信这个结果,但我相信没用,要发表在专业刊物,同行评议, 光自说自话也不行
 
顶部